These include three mutations that correlate with response to EGFR-targeted therapy (two in NSCLC and one in glioblastoma),19,20,21 one associated with anti-EGFR therapy resistance (in colorectal cancer)22 and two identified as biomarkers by the FDA.25 This evidence concerns the gene EGFR and colorectal cancer.